Scleroderma in children

Area of Science:

• Rheumatology
• Pediatric Rheumatology
• Immunology

Background:

• Juvenile systemic scleroderma (jSSc) is a rare childhood autoimmune disease.
• Limited research exclusively focuses on jSSc, with no major breakthroughs in pathogenesis, classification, or treatment in the review period.
• Progress in adult systemic scleroderma includes European efforts to establish disease activity indices.

Purpose of the Study:

• To review recent advancements in juvenile systemic scleroderma (jSSc) and adult systemic scleroderma.
• To highlight progress in classification systems and assessment methods for jSSc.
• To discuss current and emerging therapeutic options for systemic scleroderma.

Main Methods:

• Literature review of recent reports on juvenile and adult systemic scleroderma.
• Analysis of proposed classification systems for pediatric populations.
• Evaluation of European initiatives for adult systemic scleroderma disease activity indices.

Main Results:

• A proposed classification system for jSSc shows progress in defining the pediatric population.
• European efforts have yielded disease activity indices for adult systemic scleroderma, aiding standardized assessment.
• Autologous stem cell transplantation trial data published; guidelines proposed for jSSc.
• Bosentan introduced for pulmonary hypertension in systemic scleroderma offers a therapeutic gain.
• New prognostic assessment methods are emerging but require validation.

Conclusions:

• While classification and assessment tools are improving for jSSc and adult systemic scleroderma, effective disease-modifying treatments are still lacking.
• Advancements in organ-specific treatments like bosentan for pulmonary hypertension represent significant therapeutic progress.
• Further validation of new prognostic methods in larger patient cohorts is necessary.